CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 3.9% – Time to Sell?

11 Mar 2025, 16:20 by Doug Wharley · The Cerbat Gem

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) was down 3.9% during mid-day trading on Tuesday . The stock traded as low as $40.82 and last traded at $41.63. Approximately 586,834 shares traded hands during mid-day trading, a decline of 74% from the average daily volume of 2,241,707 shares. The stock had previously closed at $43.34.

Analyst Ratings Changes

A number of analysts have recently commented on CRSP shares. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. Barclays lifted their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Citigroup reduced their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $73.11.

View Our Latest Stock Analysis on CRISPR Therapeutics

CRISPR Therapeutics Price Performance

The stock’s 50-day moving average is $42.88 and its 200 day moving average is $45.71. The stock has a market cap of $3.63 billion, a price-to-earnings ratio of -9.70 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John Greene acquired 7,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 26th. The shares were bought at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the acquisition, the director now owns 7,000 shares of the company’s stock, valued at $313,950. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the company. Capital Market Strategies LLC acquired a new stake in CRISPR Therapeutics in the fourth quarter valued at $461,000. KBC Group NV boosted its position in shares of CRISPR Therapeutics by 2,047.4% in the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after buying an additional 57,696 shares in the last quarter. Geode Capital Management LLC grew its stake in CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after acquiring an additional 35,196 shares during the last quarter. State Street Corp increased its holdings in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares in the last quarter. Finally, ARK Investment Management LLC raised its position in CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

(Get Free Report)